Abstract Background and Aims: The biosimilar of Remicade®, CT-P13, recently entered the
European market. Clinical data on switching from Remicade® to CT-P13 in inflammatory …

Background Limited data are available on long-term clinical outcomes regarding the switch
from Remicade® to the infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD) …

Background CT-P13 is a biosimilar of Remicade®, an agent approved in some countries for
use in inflammatory bowel disease (IBD). Controlled clinical trials have demonstrated the …

Background: As the patents of originator biologics are expiring, biosimilar versions are
becoming available for the treatment of inflammatory bowel disease (IBD). However …

Background and Aims: A biosimilar version of infliximab [CT-P13/Remsima®] recently
entered the European market. The clinical data on its use in inflammatory bowel disease …

Objective: To assess the efficacy, tolerability, and safety of CT-P13 (Remsima®) in patients
with Crohn's disease (CD) or ulcerative colitis (UC). Methods: This was a prospective …

Abstract Background Switching from Remicade to CT-P13 allows for significant cost savings
and has been shown to be non-inferior to continued therapy with Remicade for the treatment …

Objective: The infliximab biosimilar CT-P13 (Remsima®, Inflectra®) was approved in Europe
for the treatment of inflammatory bowel disease (IBD) based on extrapolation of data from …

Background & Aims There is evidence that it is safe and effective for patients with
inflammatory bowel diseases (IBD) to switch from maintenance therapy with an original …

Background Biological agents, such as infliximab, have transformed the outcomes of
patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment …